Parametric Portfolio Associates LLC cut its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 238,026 shares of the specialty pharmaceutical company’s stock after selling 8,862 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.42% of Jazz Pharmaceuticals worth $30,501,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its stake in Jazz Pharmaceuticals by 2.2% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 457,226 shares of the specialty pharmaceutical company’s stock valued at $65,183,000 after acquiring an additional 9,797 shares during the period. HBK Sorce Advisory LLC bought a new position in Jazz Pharmaceuticals in the second quarter valued at about $324,000. Chicago Equity Partners LLC lifted its holdings in Jazz Pharmaceuticals by 152.4% in the second quarter. Chicago Equity Partners LLC now owns 16,760 shares of the specialty pharmaceutical company’s stock valued at $2,389,000 after acquiring an additional 10,120 shares during the period. Wedge Capital Management L L P NC lifted its holdings in Jazz Pharmaceuticals by 8.0% in the third quarter. Wedge Capital Management L L P NC now owns 276,013 shares of the specialty pharmaceutical company’s stock valued at $35,368,000 after acquiring an additional 20,553 shares during the period. Finally, First Trust Advisors LP boosted its position in Jazz Pharmaceuticals by 21.9% in the third quarter. First Trust Advisors LP now owns 152,223 shares of the specialty pharmaceutical company’s stock worth $19,506,000 after purchasing an additional 27,373 shares during the last quarter. 89.10% of the stock is currently owned by institutional investors.

A number of research firms have issued reports on JAZZ. Oppenheimer set a $176.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, September 26th. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 price target on the stock. in a research report on Friday, September 13th. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Friday, November 29th. Sanford C. Bernstein reissued a “market perform” rating and set a $150.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, October 14th. Finally, Barclays upped their price objective on Jazz Pharmaceuticals from $182.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company’s stock. Jazz Pharmaceuticals has an average rating of “Buy” and a consensus target price of $168.71.

In other news, CEO Bruce C. Cozadd sold 500 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total value of $65,000.00. Following the completion of the transaction, the chief executive officer now owns 311,855 shares of the company’s stock, valued at $40,541,150. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.30% of the stock is owned by insiders.

Shares of JAZZ stock opened at $146.45 on Wednesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.89 and a quick ratio of 3.71. Jazz Pharmaceuticals PLC has a one year low of $113.52 and a one year high of $153.03. The company’s fifty day moving average price is $132.98 and its 200-day moving average price is $132.88. The company has a market capitalization of $8.29 billion, a price-to-earnings ratio of 11.96, a PEG ratio of 1.18 and a beta of 1.15.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, topping the consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The company had revenue of $537.70 million during the quarter, compared to the consensus estimate of $523.92 million. During the same quarter in the prior year, the firm posted $3.58 EPS. Jazz Pharmaceuticals’s quarterly revenue was up 14.6% compared to the same quarter last year. Equities research analysts expect that Jazz Pharmaceuticals PLC will post 14.15 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: What are the benefits of a portfolio tracker?

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.